As part of our commitment to providing patients the most effective cancer treatment possible, we also maintain a Cancer Registry. The Cancer Registry contains case information on each of our patients which can be compared with data from cancer centers nationwide. By analyzing Cancer Registry data, we are able to continually improve the quality of care and treatment we provide our patients and advance cancer control research. Get information about Cancer Registries.
Clinical Trials Alliances
Through participation with national study groups such we can offer our patients investigational drug protocols. Listed below are the major cooperative groups in which we participate and the faculty members active in each.
Children’s Oncology Group (COG)
This group is the result of the recent mergers of four cancer cooperative groups -- the Children's Cancer Group (CCG), the Pediatric Oncology Group (POG), the Intergroup Rhabdomyosarcoma Study Group (IRSG) and the National Wilms' Tumor Study Group (NWTSG). It is a National Cancer Institute-supported clinical trials cooperative group devoted exclusively to childhood and adolescent cancer research. Louis Constine, M.D. has been active in the Radiation Oncology Committee and on the Core committees for Hodgkin's Disease, bone marrow transplantation, and Late Effects. He co-developed protocols in these various areas, including a recent protocol for children with advanced-stage Hodgkin's disease. More information about COG
This was the first University of Rochester Medical Center startup of 2002. Headed by Dr. Ruola Ning, its patented 3-D Cone Beam Volume Computed Tomography is being developed to significantly improve early detection of breast cancer, and to provide noninvasive diagnosis and treatment planning. The technology can also be used to visualize tiny lung tumors and to provide accurate 3-D images of vessels.
Lucid, Inc. is a Rochester, NY-based company and a leader in developing real-time medical diagnostic aids for cancer screening and evaluation of diseased tissue. In July, 2001, the University of Rochester Medical Center began a novel collaboration with Lucid, Inc. Lucid installed a VivaScope® system, a laser confocal microscope that lets physicians peer below the surface layers of the skin to diagnose problems such as skin cancer without a painful surgical biopsy, in the Department of Dermatology. Dermatology researchers in the Medical Center helped Lucid develop guidelines and a pictorial atlas for the VivaScope® device.
Get more information on:
Radiation Therapy Oncology Group (RTOG)
The Radiation Therapy Oncology Group (RTOG) is a is a National Cancer Institute-supported clinical trials cooperative group with almost 30 years of experience in running clinical trials. It is comprised of 250 of the major research institutions and is the primary cooperative group conducting clinical trials in Radiation Oncology in the U.S. and Canada. Paul Okunieff, M.D., is Principal Investigator to the RTOG for the University of Rochester. He is active as the National Chairman of the Tumor Biology Committee.
A strong affiliate program exists with several of our former residents and faculty members. These include Sandra McDonald, M.D. The Genesee Hospital, Henry Keys, M.D. and Vernon King, M.D., Albany (NY) Medical Center, Thomas Noell, M.D., Romagosa Radiation Oncology Center, Lafayette, LA, and Paul Anthony, M.D., St. Joseph's Cancer Center, Albuquerque, NM. In addition to these centers, four other institutions affiliate with us to participate in RTOG trials. This group is responsible for 70 patients being entered on RTOG studies annually. More information about RTOG
RTek Medical Systems LLC
RTek Medical Systems LLC, a privately held, Pittsford-based company was created in 1999 to commercialize a new prostate cancer treatment system developed by researchers at the University of Rochester Medical Center.
Southwest Oncology Group (SWOG)
This is one of the largest of the National Cancer Institute-supported cancer clinical trials cooperative groups in North America. The SWOG network consists of almost 4,000 of the nation’s leading physicians at 283 institutions throughout the United States and Canada. Since its inception in 1956, SWOG has helped more than 150,000 patients enrolled in clinical trials. In the last 13 years, SWOG research has led to the FDA issuance of new drug approvals for 10 cancer therapies. Many of our faculty are active on SWOG committees.
Radiation Oncology Committee
More information about SWOG
Vaccinex, Inc., was founded in 1997 by URMC scientists, Maurice Zauderer, Ph.D. and Deepak Sahasrabudhe, M.D., to develop immune system based treatments to fight cancer and other diseases. Vaccinex’s proprietary technology offers diverse applications including antigen identification, human monoclonal antibody selection, and functional gene discovery. Vaccinex plans to initiate clinical trials in mid-2003 for a promising breast cancer therapeutic. The company has raised more than $17 million in venture funding and federal grants. It has 32 employees and is located in a 33,000 sq. ft. facility in Rochester. More information about Vaccinex, Inc.
Virtual Scopics, LLC
VirtualScopics, LLC, a privately held, Pittsford-based company was created in 1999 to commercialize new analysis software that can extract complex information from ordinary CT or MRI scans. This information can be used to render three-dimensional color computer models of organs and other structures within the body. The computer analysis can provide previously unobtainable information about the progression of diseases such as cancer, osteoarthritis and multiple schlerosis. The University of Rochester has been awarded a patent pertaining to the technology and other patents that are pending. More information about Virtual Scopics, LLC